ISMRM25 - Preclinical Contrast Mechanism & Spectroscopy

ISMRM & ISMRT Annual Meeting & Exhibition • 10-15 May 2025 • Honolulu, Hawai'i

Preclinical Contrast Mechanism & Spectroscopy

Oral

Preclinical

Thursday, 15 May 2025

313C

08:15 - 10:15

Moderators: Jeff W.M. Bulte & Franz Schilling

Session Number: O-80

CME Credit

08:15		1144. NaGdF4@PDA-ALD Nanoparticles Enhance Mesenchymal Stem Cell Therapy for Ischemic Stroke: MRI Tracking and Protection Mechanisms View Presentation Video S. Wu, X. Chu, P-Y Wu, Z. Yao Huashan hospital, Fudan University, Shanghai, China Impact: This study provides a novel strategy to enhance MSC-based therapies for ischemic stroke, potentially improving patient outcomes. The nanoparticles protect MSCs might open new avenues for developing more effective cell therapies and in vivo tracking methods for regenerative medicine.
08:27		1145. Selective and targeted imaging for pancreatic cancer in a mouse model: structured polyethylene glycol as a specific MR molecular imaging agent View Presentation Video S. Swanson, N. Nelson, T. Hopkins, A. Hopkins University of Michigan, Ann Arbor, United States Impact: The delivery and MRI of the sPEG nanopolymers demonstrate a clear path to a new imaging paradigm – yielding PET-like images of sPEG and providing oncologists and radiologists with a new tool to quickly detect and diagnose solid cancers.
08:39		1146. Metabolic inhibition therapy targeting glutaminolysis in mantle cell lymphoma View Presentation Video K. Nath, P. K. Gupta, S. Wang, S. Rao, A. Shestov, N. Sen, S. Orlovskiy, C. Lobello, D. Rushmore, J. Basappa, D. Nelson, F. Arias-Mendoza, M. Wasik University of Pennsylvania, Philadelphia, United States Impact: Therapy-mediated decreased intra-tumoral concentrations of lactate and alanine measured by ¹H MRS may potentially become early and sensitive biomarkers of glutaminase inhibition in MCL and, likely, other types of malignancies.
08:51		1147. Preliminary MRI Findings for Manganese Chloride as a Novel Radiation Countermeasure Against Acute Radiation Sickness in Mice View Presentation Video A. Korotcov, M. Majji, N. Rakhilin, G. Holmes-Hampton, A. Ahmed, B. Knollmann-Ritschel, M. Hood Uniformed Services University, Bethesda, United States Impact: For radiation research being conducted in animals, serial MR imaging can provide important information on health status. Establishing MRI techniques and postprocessing pipelines, plus tools for histological correlation, MRI will become a key tool to evaluate animals in radiation research.
09:03		1148. In Vivo Fluorine Metabolic Imaging (FMI) of Cancer View Presentation Video D. Cohen, L. Saad, L. Avram, H. Allouche-Arnon, A. Bar-Shir Weizmann Institute of Science, Rehovot, Israel Impact: FMI with 3FDGal as an 19F-MRI tracer represents a revolutionary shift in oncologic imaging. By concurrently mapping sugar oxidizing/reducing enzymes, tumor categorization becomes available at the molecular level, regardless of glycolysis-dependence, opening up new frontiers in cancer research and detection.
09:15		1149. Imaging tumor extracellular pH using PET/MRI co-agents View Presentation Video C. Dhakan, X. Liang, L. Palagi, J. DeLaCerda, F. W. Schuler, M. D. Pagel University of Wisconsin - Madison, Madison, United States Impact: This dual PET/MRI approach provides a reliable, non-invasive method for measuring tumor pHe, potentially transforming how tumor acidosis is monitored. It could lead to earlier, more accurate assessments of treatment response, enhancing personalized cancer therapy strategies.
09:27		1150. From PET to MRI: In vivo Mapping the HSV1-TK Reporter Gene with “hot-spot” 2H-MRI Using Synthetic Deuterated Thymidine Analog View Presentation Video H. Allouche-Arnon, L. Mimoun, B. Subramani, E. Montrazi, A. Bar-Shir Weizmann Institute of science, Rehovot, Israel Impact: The successful implementation of the proposed ²H-MRI reporter system will allow the longitudinal quantitative mapping of a reporter gene expression, elucidating the kinetics and efficiency of gene and cell therapies employed in basic research and the clinic.
09:39		1151. Deuterium metabolic imaging of response to precision therapy in BRAF-V600E mutant gliomas View Presentation Video G. Batsios, S. Udutha, A. M. Gillespie, C. Petritsch, S. Mueller, P. Viswanath University of Caifornia, San Francisco, San Francisco, United States Impact: Our studies mechanistically link BRAF/MEK inhibition with downregulation of glycolysis and identify [6,6’-²H]-glucose as a novel contrast agent for imaging early response to therapy. Clinical translation of our studies will enable precision imaging of response to therapy for BRAF-mutant gliomas.
09:51		1152. Dynamic CEST Imaging of Extracellular Lactate In Vivo in Subcutaneous Tumors using PARACEST Shift Reagents PDF Poster View Presentation Video R. Chiaffarelli, P. Cruz, J. Cotton, T. Kelm, S. Lee, M. Ghaderian, M. Zimmermann, C. Geraldes, P. Jurek, A. Martins University Hospital Tuebingen, Tuebingen, Germany Impact: EuPCTA and YbPCTA enable selective imaging of extracellular lactate, allowing detection of metabolic compartments in the tumor microenvironment. PCTA-based complexes represent a scaffold for the optimization of metabolic responsive imaging probes to map tumor heterogeneity and aggressiveness.
10:03		1153. Parallel Detection of MRI and 1H MRSI for Efficient Multi-Contrast Anatomical and Metabolic Imaging. View Presentation Video R. de Graaf, M. Thomas, H. De Feyter Yale University, New Haven, United States Impact: Parallel detection of MRI and ¹H MRSI eliminates the extra scan time inherent to standard, sequential acquisitions. The increased efficiency can be used to achieve shorter examinations in clinical or high-throughput environments or allow higher-resolution and/or additional contrast research scans.

Similar Session(s)